

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1<sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p><b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p><b>Kind Attn.:</b> Famroze Pochara Asst. Vice President</p>
<p><b>Date:</b> July 12, 2016</p>	
<p><b>Re.:</b> Announcement</p>	


Dear Sir / Madam,

We hereby inform that Cadila Healthcare Limited announced that its US based 100% subsidiary company Zydus Pharmaceuticals (USA) Inc. (Zydus) will begin informing today its customers that Zydus will start selling an authorized generic of Asacol<sup>®</sup> HD (mesalamine delayed –release tablets 800 mg) in the United States commencing on August 1, 2016.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **Cadila Healthcare Limited**

  
**Upen H. Shah**  
Company Secretary

